Format

Send to

Choose Destination
Neuroophthalmology. 2017 Apr 19;41(4):192-197. doi: 10.1080/01658107.2017.1304425. eCollection 2017 Aug.

An Estimation of the Risk of Pseudotumor Cerebri among Users of the Levonorgestrel Intrauterine Device.

Author information

1
Department of Ophthalmology and Visual Sciences; John A. Moran Eye Center, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
2
Department of Neurology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
3
Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
4
Department of Operations and Information Systems, David Eccles School of Business, University of Utah, Salt Lake City, Utah, USA.
5
Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Glostrup, Denmark.

Abstract

Because of a previous association of pseudotumor cerebri (PTC) with levonorgestrel, we wished to evaluate the use of levonorgestrel-eluting intrauterine devices ("levonorgestrel intrauterine systems", LNG-IUS) in our University of Utah and Rigshospitalet PTC patients. In our retrospective series, PTC prevalence was approximately 0.18% and 0.15% in the LNG-IUS population versus 0.02% and 0.04% in the non-LNG-IUS population (Utah and Rigshospitalet, respectively), with no significant differences in PTC signs and symptoms among the two groups. Our investigation suggests that women with an LNG-IUS may have increased risk of developing PTC but does not suggest an LNG-IUS can cause PTC.

KEYWORDS:

Contraception; idiopathic intracranial hypertension; intrauterine system; levonorgestrel; pseudotumor cerebri

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center